These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3711314)

  • 1. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis.
    Vernet-der Garabedian B; Morel E; Bach JF
    J Neuroimmunol; 1986 Jul; 12(1):65-74. PubMed ID: 3711314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.
    Vernet-der Garabedian B; Bach JF; Morel E
    Clin Exp Immunol; 1987 Apr; 68(1):130-7. PubMed ID: 3652512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heterogeneity of antibodies blocking the binding of bungarotoxin to the acetylcholine receptor in myasthenia].
    Vernet-der-Garabédian B; Morel E; Bach JF
    C R Acad Sci III; 1984; 298(16):449-56. PubMed ID: 6428718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of TE671 cells.
    Pachner AR
    Neurology; 1989 Aug; 39(8):1057-61. PubMed ID: 2761699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-bungarotoxin blocking antibodies in neonatal myasthenia gravis: frequency and selectivity.
    Vernet-der Garabedian B; Eymard B; Bach JF; Morel E
    J Neuroimmunol; 1989 Jan; 21(1):41-7. PubMed ID: 2908881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis.
    Hara H; Hayashi K; Ohta K; Itoh N; Nishitani H; Ohta M
    Clin Chem; 1993 Oct; 39(10):2053-7. PubMed ID: 8403390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic and immunologic studies in experimental autoimmune myasthenia gravis and myasthenia gravis.
    Trotter JL; Ringel SP; Cook JD; Engel WK; Eldefrawi ME; McFarlin DE
    Neurology; 1977 Dec; 27(12):1120-4. PubMed ID: 73154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass.
    Whiting PJ; Vincent A; Newsom-Davis J
    J Neuroimmunol; 1983 Aug; 5(1):1-9. PubMed ID: 6874919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple forms of anti-acetylcholine receptor antibody in myasthenia gravis.
    Mittag T; Massa T; Kornfeld P; Papatestas A; Bender A; Genkins G
    Muscle Nerve; 1981; 4(1):16-25. PubMed ID: 6164920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of radioimmunoassay procedures for determination of anti-acetylcholine receptor antibodies in the sera of patients with myasthenia gravis.
    Carter B; Harrison R; Lunt GG; Morris H; Savage-Marengo T; Stephenson FA
    Ann Clin Biochem; 1981 May; 18(Pt 3):146-52. PubMed ID: 7283364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical enzyme immunoassay for anti-acetylcholine receptor antibodies in myasthenia gravis.
    Furukawa S; Akazawa S; Furukawa Y; Kamo I; Satoyoshi E; Hayashi K
    J Neuroimmunol; 1984; 6(6):397-409. PubMed ID: 6384263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J; Wang ZY; Link H
    J Neurol Sci; 1994 Feb; 121(2):190-3. PubMed ID: 8158214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.
    Besinger UA; Toyka KV; Hömberg M; Heininger K; Hohlfeld R; Fateh-Moghadam A
    Neurology; 1983 Oct; 33(10):1316-21. PubMed ID: 6684226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels.
    Vincent A; Newsom-Davis J
    Clin Exp Immunol; 1985 Jun; 60(3):631-6. PubMed ID: 2410169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-presynaptic membrane receptor antibodies in myasthenia gravis.
    Lu CZ; Link H; Mo XA; Xiao BG; Zhang YL; Qin Z
    J Neurol Sci; 1991 Mar; 102(1):39-45. PubMed ID: 1856731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future therapeutic strategies in autoimmune myasthenia gravis.
    Psaridi-Linardaki L; Mamalaki A; Tzartos SJ
    Ann N Y Acad Sci; 2003 Sep; 998():539-48. PubMed ID: 14592926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis.
    Aurangzeb S; Tariq M; Irshad M; Badshah M; Khan RS
    J Pak Med Assoc; 2009 May; 59(5):289-92. PubMed ID: 19438131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sera from myasthenia gravis patients and of alpha-bungarotoxin on acetylcholinesterase during in vitro neuromuscular synaptogenesis.
    de la Porte S; Ragueh F; Eymard B; Courbin P; Chapron J; Koenig J
    J Neurol Sci; 1993 Jul; 117(1-2):92-102. PubMed ID: 8410074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG).
    Loutrari H; Kokla A; Trakas N; Tzartos SJ
    Clin Exp Immunol; 1997 Sep; 109(3):538-46. PubMed ID: 9328134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.